Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 19.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,842 shares of the company’s stock after selling 1,425 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Mineralys Therapeutics were worth $72,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after buying an additional 989 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Mineralys Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company’s stock worth $2,645,000 after acquiring an additional 1,307 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Mineralys Therapeutics by 2.7% in the fourth quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company’s stock valued at $804,000 after purchasing an additional 1,711 shares during the period. Wells Fargo & Company MN increased its position in Mineralys Therapeutics by 19.1% during the fourth quarter. Wells Fargo & Company MN now owns 23,714 shares of the company’s stock worth $292,000 after purchasing an additional 3,802 shares during the last quarter. Finally, Barclays PLC raised its stake in Mineralys Therapeutics by 21.4% during the fourth quarter. Barclays PLC now owns 46,396 shares of the company’s stock worth $571,000 after purchasing an additional 8,178 shares during the period. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Trading Up 1.6 %

Shares of MLYS opened at $13.56 on Tuesday. The firm has a market capitalization of $879.72 million, a P/E ratio of -3.73 and a beta of -0.39. The stock’s fifty day simple moving average is $13.00 and its 200 day simple moving average is $12.35. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02. Sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Analyst Ratings Changes

MLYS has been the subject of several research reports. The Goldman Sachs Group lowered their price objective on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. HC Wainwright increased their target price on Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, April 2nd. Finally, Guggenheim reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.

Insider Buying and Selling at Mineralys Therapeutics

In related news, major shareholder Samsara Biocapital Gp, Llc acquired 600,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $13.50 per share, with a total value of $8,100,000.00. Following the completion of the transaction, the insider now directly owns 5,674,916 shares of the company’s stock, valued at $76,611,366. This trade represents a 11.82 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the transaction, the chief financial officer now directly owns 215,340 shares in the company, valued at $2,597,000.40. This trade represents a 4.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,213 shares of company stock valued at $1,360,567 over the last three months. 33.24% of the stock is owned by company insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.